Prolactin (PRL) affects many organic functions, including metabolism control, glucose tolerance, and insulin resistance. This study aimed at evaluating the relationship between PRL and basal glucose metabolism in 17 women with microprolactinomas. Fasting glycemia, insulin, Homeostatic Model Assessment-Insulin Resistance (HOMA-IR), and Homeostatic Model Assessment-beta (HOMA-beta) were evaluated in six non-diabetic non-obese patients with normoprolactinemia (NPRL), 11 with hyperprolactinemia (EPRL), and 11 healthy controls. Patients were also compared according to dopamine agonist use and menstrual status. Normo and hyperprolactinemic patients and controls had serum PRL levels of 15.5 ± 8.3 vs 73.5 ± 44.9 vs 13.8 ± 5.7 ng/mL, respectively. Glycemia, insulinemia, HOMA-IR and HOMA-beta were not statistically different between these three groups (p:0.3359, 0.8951, 0.8681, and 0.2098, respectively). The four variables did not correlate with PRL levels.
Metabolic parameters did not differ between eumenorrheic and oligomenorrheic women (p:0.1247, 0.2994, 0.1954, and 0.1767 for glycemia, insulinemia, HOMA-IR, and HOMA-beta, respectively). Bromocriptine (BC) users showed lower fasting glycemia than non-users of dopamine agonist (p=0.0021). We concluded that hyperprolactinemia did not result in impairment of glucose metabolism in women with prolactinoma.
Adilson Lamounier Filho, Rafaela Marchon de Sousa, Mariana Coelho Botelho, João Bosco Nascimento, Erika César de Oliveira Naliato and Alice Helena Dutra Violante*